4-Morpholinocarbonyl-1-butyne → 1-(2-Diethylaminoethyl)-4-trifluoromethyl-6-(4-morpholinocarbonyl-1-butynyl)-3-hydroxy-3-(phenyl)oxindole
Reaction equation
[CH2:1]([N:3]([CH2:28][CH3:29])[CH2:4][CH2:5][N:6]1[C:14]2[C:9](=[C:10]([C:16]([F:19])([F:18])[F:17])[CH:11]=[C:12](I)[CH:13]=2)[C:8]([OH:26])([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][CH:21]=2)[C:7]1=[O:27])[CH3:2].[O:30]1[CH2:35][CH2:34][N:33]([C:36]([CH2:38][CH2:39][C:40]#[CH:41])=[O:37])[CH2:32][CH2:31]1>>[CH2:1]([N:3]([CH2:28][CH3:29])[CH2:4][CH2:5][N:6]1[C:14]2[C:9](=[C:10]([C:16]([F:19])([F:18])[F:17])[CH:11]=[C:12]([C:41]#[C:40][CH2:39][CH2:38][C:36]([N:33]3[CH2:34][CH2:35][O:30][CH2:31][CH2:32]3)=[O:37])[CH:13]=2)[C:8]([OH:26])([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][CH:21]=2)[C:7]1=[O:27])[CH3:2]Participants
3
Procedure
The title compound (65.2 mg, 88%) was prepared from 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-iodo-3-hydroxy-3-(phenyl)oxindole (57.2 mg) and 4-morpholinocarbonyl-1-butyne (31.1 mg) by the procedure similar to that described in Reference Example 21. The compound obtained was further purified by reverse phase HPLC with water-acetonitrile-trifluoroacetic acid.
Workup
- customThe compound obtained
- customwas further purified by reverse phase HPLC with water-acetonitrile-trifluoroacetic acid
Sources & evidence
- ORD record
- ord-1f79933e9a2c4693b8b42bebe055deec
- Source dataset
- uspto-grants-2003_06
- Patent number
- US06576656B1
Reaction notes
Loading…